Cargando…
The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial
BACKGROUND: P2X3 receptor antagonists seem to have a promising potential for treating patients with refractory chronic cough. In this double-blind, randomized, placebo-controlled study, we investigated the efficacy, safety, and tolerability of the novel selective P2X3 receptor antagonist filapixant...
Autores principales: | Friedrich, Christian, Francke, Klaus, Birring, Surinder S., van den Berg, Jan Willem K., Marsden, Paul A., McGarvey, Lorcan, Turner, Alice M., Wielders, Pascal, Gashaw, Isabella, Klein, Stefan, Morice, Alyn H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088222/ https://www.ncbi.nlm.nih.gov/pubmed/37041539 http://dx.doi.org/10.1186/s12931-023-02384-8 |
Ejemplares similares
-
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
por: Morice, Alyn, et al.
Publicado: (2021) -
Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021) -
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020) -
Treating acute cough: wet versus dry – have we got the paradigm wrong?
por: Morice, Alyn H., et al.
Publicado: (2015) -
Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)